|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 669.20 USD | +2.33% |
|
+8.20% | +19.15% |
| 10-23 | Medpace's Bookings, Pre-Backlog Trends Support Growth Outlook, UBS Says | MT |
| 10-23 | UBS Adjusts Price Target on Medpace to $700 From $673, Maintains Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MEDPACE HOLDINGS, INC. | Other Biotechnology & Medical Research | +2.33% | +8.20% | +19.15% | +12.17% | +257.78% | 18.72B |  | | |
- Stock Market
- Stocks
- MEDP Stock
- Charts Medpace Holdings, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
